Min-Sun Kwak

Min-Sun Kwak


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Gastroenterology
Verified
Journal Article
Closed access
EJEun Hyo Jin
Eun Hyo Jin
Dongheon LeeDongheon Lee
Dongheon Lee
JBJung Ho Bae
Jung Ho Bae
HKHae Yeon Kang
Hae Yeon Kang
MKMin-Sun Kwak
Min-Sun Kwak
JKJoo Sung Kim
Joo Sung Kim

13 May 2024 in Hepatology
Verified
Journal Article
Closed access
MKMin-Sun Kwak
Min-Sun Kwak
HKHyun-Seok Kim
Hyun-Seok Kim
ZJZ. Gordon Jiang
Z. Gordon Jiang
YYYee Hui Yeo
Yee Hui Yeo
HTHirsh D. Trivedi
Hirsh D. Trivedi
JYJudong Yang
Judong Yang
Background and Aims: A new term, metabolic dysfunction–associated steatotic liver disease (MASLD), has been proposed by a multi-society expert panel. However, it remains unclear whether hepatic steatosis per se in MASLD contributes to an increased risk of mortality in individuals with any cardio-metabolic risk factor (CMRF), which is also a significant risk factor for increased mortality. This study aimed to compare all-cause and cause-specific mortality between the “MASLD/MetALD” and “no steatotic liver disease (SLD)” groups in individuals with any CMRF. Approach and Results: A population-based cohort study was conducted using 10,750 participants of the Third National Health and Nutrition Examination Survey. All-cause and cause-specific (cardiovascular, cancer, diabetes, and liver) mortality risks were compared between the “MASLD,” “MetALD,” and “no SLD” groups using the Cox proportional hazards model with complex survey design weights, adjusted for confounders. Over 26 years, the “MASLD” group did not show significantly increased all-cause (adjusted HR 1.04[95% CI: 0.95–1.14], p = 0.413), cardiovascular (0.88 [0.75–1.04], p = 0.139), or cancer (1.06[0.84–1.33], p = 0.635) mortality risk compared to the “no SLD” group in individuals with any CMRF. The MetALD group was associated with increased all-cause (1.41 [1.05–1.89], p = 0.022), cancer (2.35 [1.33–4.16], p = 0.004), and liver (15.04 [2.96–76.35], p = 0.002) mortality risk compared with the no SLD group. This trend was more pronounced in the MetALD group with advanced fibrosis assessed by Fibrosis-4 (FIB-4). Conclusions: In individuals with CMRF, the presence of steatotic liver disease (MASLD) alone did not increase the risk of mortality, except in cases with more alcohol consumption (MetALD). Therefore controlling metabolic risk factors and reducing alcohol consumption in people with MASLD or MetALD will be crucial steps to improve long-term health outcomes.

29 November 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
ECEun Ju Cho
Eun Ju Cho
GJGucheol Jung
Gucheol Jung
MKMin-Sun Kwak
Min-Sun Kwak
JYJong-In Yang
Jong-In Yang
JYJeong-Yoon Yim
Jeong-Yoon Yim
GCGoh Eun Chung
Goh Eun Chung
Nonalcoholic fatty liver disease (NAFLD) is increasing worldwide, highlighting the importance of early and accurate detection and the appropriate management of NAFLD. However, ultrasonography (US) is not included in many mass screening programs, and people have limited access to it. The aim of this study is to validate the fatty liver index (FLI) and investigate the optimal cutoff value for predicting NAFLD in an asymptomatic population. We conducted a retrospective cohort study in Korea. All subjects who underwent health checkup exams, including abdominal US, controlled attenuation parameter (CAP) and blood testing, were enrolled. Analyses of the area under the receiver operating characteristic curve (AUROC) were used to evaluate the diagnostic accuracy and to calculate the optimal FLI cutoff for US-NAFLD. Among the 4009 subjects (mean age 54.9 years, 83.5% male), the prevalence of US-diagnosed NAFLD and CAP-defined hepatic steatosis was 61.4% and 55.4%. The previously used cutoff of FLI = 60 showed poor performance in predicting US-diagnosed NAFLD, with an AUROC of 0.63 (0.62–0.64), and CAP-defined NAFLD, with an AUROC 0.63 (0.62–0.64). The optimal FLI cutoff values to discriminate fatty liver detected by US were 29 for the entire population, with an AUROC of 0.82 (0.81–0.84). The sex-specific values were 31 for males and 18 for females (sensitivity 72.8% and 73.4%; specificity 74.2% and 85.0%, respectively). The FLI cutoff for US-diagnosed NAFLD can be set as 29 for the entire Korean population. Considering the sex dimorphism in NAFLD, different cutoff values are suggested to predict US-diagnosed NAFLD. These results may be helpful in the accurate non-invasive diagnosis of NAFLD.

1 July 2019 in Digestive and Liver Disease
Verified
Journal Article
Closed access
MKMin-Sun Kwak
Min-Sun Kwak
JYJeong Yoon Yim
Jeong Yoon Yim
AYAnn Yi
Ann Yi
GCGoh Eun Chung
Goh Eun Chung
JYJong In Yang
Jong In Yang
DNDong-Young Noh
Dong-Young Noh

12 March 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
CLChang-Hoon Lee
Chang-Hoon Lee
KHKyung-Do Han
Kyung-Do Han
DKDa Hye Kim
Da Hye Kim
MKMin-Sun Kwak
Min-Sun Kwak
Aims: Non-alcoholic fatty liver disease (NAFLD) has a dynamic disease course, therefore repeated measurements of NAFLD status could have benefits rather than single one. The aim of this study was to investigate the effects of persistent NAFLD on the incidence of myocardial infarction (MI) and stroke and all-cause mortality by using repeated measurement of fatty liver index (FLI).Methods: About 3 million subjects who had undergone the health screening four times from 2009 until 2013 were included. NAFLD was defined as an FLI ≥60. FLI points were defined as the number of times participants meeting the criteria of NAFLD (0–4). Outcomes included all-cause mortality, MI, and stroke.Results: The higher the FLI points, the higher the risk of all-cause mortality, MI, and stroke (P for trend <0.001, all). Subjects with four FLI points had a higher risk of all-cause mortality (aHR, 1.86; 95% CI, 1.75–1.98; P < 0.001), incidence of MI (aHR, 1.3; 95% CI, 1.21–1.40; P < 0.001), and stroke (aHR, 1.27; 95% CI, 1.19–1.37; P < 0.001) after adjustment for age, sex, smoking, alcohol consumption, income, hypertension, dyslipidemia, diabetes, body mass index, and physical activity. When the 1st and the last FLI were compared, the “incident NAFLD” group had a higher risk for death compared to the “no NAFLD” group (aHR, 1.46; 95% CI, 1.37–1.55), and the “regression of NAFLD” group had a decreased risk for death compared to the “persistent NAFLD” group (aHR, 0.83; 95% CI, 0.77–0.89).Conclusion: Repeated evaluations of NAFLD status based on FLI measurements could help physicians identify higher-risk groups in terms of mortality, MI, and stroke. The association between FLI worsening or improvement and outcomes also suggests clinical benefits of the prevention and treatment of NAFLD.

16 April 2018 in Liver International
Verified
Journal Article
Closed access
PDF file
CLChang‐Hoon Lee
Chang‐Hoon Lee
SCSeung Ho Choi
Seung Ho Choi
GCGoh Eun Chung
Goh Eun Chung
BPBoram Park
Boram Park
MKMin-Sun Kwak
Min-Sun Kwak